Drug Profile
Research programme: peptide therapeutics - PhaseBio Pharmaceuticals
Alternative Names: CNP-ELP; GLP2-ELP; Insulin-ELP; PB 1120; VIP-ELP-120Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator PhaseBio Pharmaceuticals
- Class Biopolymers; Drug conjugates; Insulins; Pancreatic hormones; Peptide hormones; Recombinant fusion proteins
- Mechanism of Action C Type natriuretic peptide replacements; Ornithine decarboxylase stimulants; Peptide replacements; Phosphokinase stimulants; Protein tyrosine kinase stimulants; Vasoactive intestinal peptide receptor agonists; Vasoactive intestinal peptide type II receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Achondroplasia; Diabetes mellitus; Short bowel syndrome
- Discontinued Cystic fibrosis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Achondroplasia in USA (SC, Injection)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Short-bowel-syndrome in USA (SC, Injection)
- 30 Jun 2021 PhaseBio Pharmaceuticals has patent protection for ELP Technology in USA